Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The c-Jun NH2-terminal kinase (JNK) signaling pathway is central to the cell response to stress, inflammatory signals, and toxins. While selective inhibitors are known for JNKs and for various upstream MAP3Ks, no selective inhibitor is reported for MKK7--one of two direct MAP2Ks that activate JNK. Here, using covalent virtual screening, we identify selective MKK7 covalent inhibitors. We optimized these compounds to low-micromolar inhibitors of JNK phosphorylation in cells. The crystal structure of a lead compound bound to MKK7 demonstrated that the binding mode was correctly predicted by docking. We asserted the selectivity of our inhibitors on a proteomic level and against a panel of 76 kinases, and validated an on-target effect using knockout cell lines. Lastly, we show that the inhibitors block activation of primary mouse B cells by lipopolysaccharide. These MKK7 tool compounds will enable better investigation of JNK signaling and may serve as starting points for therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Liu, Z.-G., Hsu, H., Goeddel, D. V., & Karin, M. (1996) · Cell · doi:10.1016/s0092-8674(00)81375-6 · Cited by 1,937
Central nervous system multiparameter optimization desirability: Application in drug discovery
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00029 · Cited by 653
Targeting JNK for therapeutic benefit: from junk to gold?
Manning, A. M., & Davis, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1132 · Cited by 585
The JIP Group of Mitogen-Activated Protein Kinase Scaffold Proteins
Yasuda, J., Whitmarsh, A. J., Cavanagh, J., Sharma, M., & Davis, R. J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.7245 · Cited by 458
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
Wu, P., Nielsen, T. E., & Clausen, M. H. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.008 · Cited by 457
Structure-based design of targeted covalent inhibitors
Lonsdale, R., & Ward, R. A. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00220c · Cited by 344
Current Development Status of MEK Inhibitors
Cheng, Y., & Tian, H. (2017) · Molecules · doi:10.3390/molecules22101551 · Cited by 291
Research works printed but not linked: 63
- Adams, 2016, Fragment-based drug discovery of potent and selective MKK3/6 inhibitors, Bioorg. Med. Chem. Lett., 26, 1086, 10.1016/j.bmcl.2015.11.054 · doi:10.1016/j.bmcl.2015.11.054
- Bubici, 2014, JNK signalling in cancer: in need of new, smarter therapeutic targets, Br. J. Pharmacol., 171, 24, 10.1111/bph.12432 · DOI · Paper page
- Chaikuad, 2018, The cysteinome of protein kinases as a target in drug development, Angew. Chem. Int. Ed., 57, 4372, 10.1002/anie.201707875 · DOI · Paper page
- Cohen, 2005, Structural bioinformatics-based design of selective, irreversible kinase inhibitors, Science, 308, 1318, 10.1126/science1108367 · DOI · Paper page
- Correy, 2017, Overcoming insecticide resistance through computational inhibitor design, bioRxiv
- Cuenda, 1998, Differential activation of stress-activated protein kinase kinases SKK4/MKK7 and SKK1/MKK4 by the mixed-lineage kinase-2 and mitogen-activated protein kinase kinase (MKK) kinase-1, Biochem. J., 333, 11, 10.1042/bj3330011 · DOI · Paper page
- Davies, 2012, Exploring the function of the JNK (c-Jun N-terminal kinase) signalling pathway in physiological and pathological processes to design novel therapeutic strategies, Biochem. Soc. Trans., 40, 85, 10.1042/BST20110641 · DOI · Paper page
- Dhanasekaran, 2017, JNK-signaling: a multiplexing hub in programmed cell death, Genes Cancer, 8, 682, 10.18632/genesandcancer.155 · DOI · Paper page
- Egorina, 2006, In-cell western assay: a new approach to visualize tissue factor in human monocytes, J. Thromb. Haemost., 4, 614, 10.1111/j.1538-7836.2005.01781.x · DOI
- Emsley, 2004, Coot: model-building tools for molecular graphics, Biol. Crystallogr., 60, 2126, 10.1107/S0907444904019158 · DOI · Paper page
- Fabian, 2005, A small molecule-kinase interaction map for clinical kinase inhibitors, Nat. Biotechnol., 23, 329, 10.1038/nbt1068 · DOI · Paper page
- Flanagan, 2014, Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors, J. Med. Chem., 57, 10072, 10.1021/jm501412a · DOI · Paper page
- Fleming, 2000, Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7, Biochem. J., 352, 145, 10.1042/bj3520145 · DOI · Paper page
- Han, 2001, c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis, J. Clin. Invest., 108, 73, 10.1172/JCI12466 · DOI · Paper page
- Jaeschke, 2007, Metabolic stress signaling mediated by mixed-lineage kinases, Mol. Cell, 27, 498, 10.1016/j.molcel.2007.07.008 · DOI
- Kabsch, 2010, XDS, Acta Crystallogr. D Biol. Crystallogr., 66, 125, 10.1107/S0907444909047337 · DOI · Paper page
- Kathman, 2016, Covalent tethering of fragments for covalent probe discovery, Med. Chem. Commun., 7, 576, 10.1039/C5MD00518C · DOI
- Kinoshita, 2017, High-resolution structure discloses the potential for allosteric regulation of mitogen-activated protein kinase kinase 7, Biochem. Biophys. Res. Commun., 493, 313, 10.1016/j.bbrc.2017.09.025 · DOI
- Krenitsky, 2012, Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor, Bioorg. Med. Chem. Lett., 22, 1433, 10.1016/j.bmcl.2011.12.027 · DOI
- Lagoutte, 2017, Covalent inhibitors: an opportunity for rational target selectivity, Curr. Opin. Chem. Biol., 39, 54, 10.1016/j.cbpa.2017.05.008 · DOI · Paper page
- Lanning, 2014, A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors, Nat. Chem. Biol., 10, 1, 10.1038/nchembio.1582 · DOI · Paper page
- Lawler, 1998, Synergistic activation of SAPK1/JNK1 by two MAP kinase kinases in vitro, Curr. Biol., 8, 1387, 10.1016/S0960-9822(98)00019-0 · DOI · Paper page
- Leproult, 2011, Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors, J. Med. Chem., 54, 1347, 10.1021/jm101396q · DOI · Paper page
- Liu, 2013, Developing irreversible inhibitors of the protein kinase cysteinome, Chem. Biol., 20, 146, 10.1016/j.chembiol.2012.12.006 · DOI · Paper page
- Lomaga, 1999, TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling, Genes Dev., 13, 1015, 10.1101/gad.13.8.1015 · DOI · Paper page
- Mazzitelli, 2011, The loss of c-Jun N-terminal protein kinase activity prevents the amyloidogenic cleavage of amyloid precursor protein and the formation of amyloid plaques in vivo, J. Neurosci., 31, 16969, 10.1523/JNEUROSCI.4491-11.2011 · DOI
- Messoussi, 2014, Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents, Chem. Biol., 21, 1433, 10.1016/j.chembiol.2014.09.007 · DOI
- Minguet, 2008, Enhanced B-cell activation mediated by TLR4 and BCR crosstalk, Eur. J. Immunol., 38, 2475, 10.1002/eji.200738094 · DOI
- Morishima, 2001, Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand, J. Neurosci., 21, 7551, 10.1523/JNEUROSCI.21-19-07551.2001 · DOI · Paper page
- Müller, 2015, The ins and outs of selective kinase inhibitor development, Nat. Chem. Biol., 11, 818, 10.1038/nchembio.1938 · DOI · Paper page
- Murshudov, 2011, REFMAC 5 for the refinement of macromolecular crystal structures, Biol. Crystallogr., 67, 355, 10.1107/S0907444911001314 · DOI · Paper page
- Nelson, 2013, Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC, Onco Targets Ther., 6, 135
- Nnadi, 2018, Novel K-Ras G12C switch-II covalent binders destabilize ras and accelerate nucleotide exchange, J. Chem. Inf. Model., 58, 464, 10.1021/acs.jcim.7b00399 · DOI · Paper page
- Peng, 2013, Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors, J. Med. Chem., 56, 3889, 10.1021/jm400072p · DOI
- Regot, 2014, Resource high-sensitivity measurements of multiple kinase activities in live single cells, Cell, 157, 1724, 10.1016/j.cell.2014.04.039 · DOI · Paper page
- Roulston, 1998, Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor alpha, J. Biol. Chem., 273, 10232, 10.1074/jbc.273.17.10232 · DOI · Paper page
- Roy, 2008, Role of the JNK signal transduction pathway in inflammatory bowel disease, World J. Gastroenterol., 14, 200, 10.3748/wjg.14.200 · DOI
- Sabapathy, 2012, Role of the JNK pathway in human diseases, Prog. Mol. Biol. Transl. Sci., 106, 145, 10.1016/B978-0-12-396456-4.00013-4 · DOI
- Schirmer, 2006, Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides, Proc. Natl. Acad. Sci. U S A, 103, 4234, 10.1073/pnas.0600445103 · DOI · Paper page
- Schramek, 2011, The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression, Nat. Genet., 43, 212, 10.1038/ng.767 · DOI
- Sogabe, 2015, 5Z-7-Oxozeaenol covalently binds to MAP2K7 at Cys218 in an unprecedented manner, Bioorg. Med. Chem. Lett., 25, 593, 10.1016/j.bmcl.2014.12.011 · DOI
- Sogabe, 2016, A crucial role of Cys218 in configuring an unprecedented auto-inhibition form of MAP2K7, Biochem. Biophys. Res. Commun., 473, 476, 10.1016/j.bbrc.2016.03.036 · DOI
- Tournier, 2001, MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines, Genes Dev., 15, 1419, 10.1101/gad.888501 · DOI · Paper page
- Ung, 2015, DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors, ACS Chem. Biol., 10, 269, 10.1021/cb500696t · DOI
- Ung, 2018, Redefining the protein kinase conformational space with machine learning, Cell Chem. Biol., 25, 10.1016/j.chembiol.2018.05.002 · DOI · Paper page
- Verma, 2012, The critical role of JNK in the ER-mitochondrial crosstalk during apoptotic cell death, J. Cell. Physiol., 227, 1791, 10.1002/jcp.22903 · DOI
- Volkamer, 2015, Pocketome of human kinases: prioritizing the ATP binding sites of (yet) untapped protein kinases for drug discovery, J. Chem. Inf. Model., 55, 538, 10.1021/ci500624s · DOI
- Wager, 2010, Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes, ACS Chem. Neurosci., 1, 420, 10.1021/cn100007x · DOI · Paper page
- Wang, 2007, Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease, Neurology, 69, 1480, 10.1212/01.wnl.0000277648.63931.c0 · DOI · Paper page
- Wang, 2012, Distinct signaling properties of mitogen-activated protein kinase kinases 4 (MKK4) and 7 (MKK7) in embryonic stem cell, J. Biol. Chem., 287, 2787, 10.1074/jbc.M111.281915 · DOI
- Ward, 2015, Structure-guided design of highly selective and potent covalent inhibitors of ERK1/2, J. Med. Chem., 58, 4790, 10.1021/acs.jmedchem.5b00466 · DOI
- Watanabe, 2017, Protein crystallography beamline BL2S1 at the Aichi synchrotron, J. Synchrotron Radiat., 24, 338, 10.1107/S1600577516018579 · DOI
- Weerapana, 2010, Quantitative reactivity profiling predicts functional cysteines in proteomes, Nature, 468, 790, 10.1038/nature09472 · DOI · Paper page
- Winn, 2011, Overview of the CCP 4 suite and current developments, Biol. Crystallogr., 67, 235, 10.1107/S0907444910045749 · DOI · Paper page
- Yarza, 2016, c-Jun N-terminal kinase (JNK) signaling as a therapeutic target for Alzheimer’s disease, Front. Pharmacol., 6, 1, 10.3389/fphar.2015.00321 · DOI · Paper page
- Yazawa, 2003, CD19 regulates innate immunity by the toll-like receptor RP105 signaling in B lymphocytes, Immunobiology, 102, 1374
- Zeke, 2016, JNK Signaling : Regulation and Functions Based on Complex Protein- Protein Partnerships, Microbiol. Mol. Biol. Rev., 80, 793, 10.1128/MMBR.00043-14 · DOI · Paper page
- Zhang, 2013, Discovery of potent and selective covalent inhibitors of JNK, Chem. Biol., 19, 140, 10.1016/j.chembiol.2011.11.010 · DOI · Paper page
- Zhao, 2014, The clinical development of MEK inhibitors, Nat. Rev. Clin. Oncol., 11, 385, 10.1038/nrclinonc.2014.83 · DOI · Paper page
- Zhao, 2018, Progress with covalent small-molecule kinase inhibitors, Drug Discov. Today, 23, 727, 10.1016/j.drudis.2018.01.035 · DOI · Paper page
- Zhao, 2017, Determining cysteines available for covalent inhibition across the human kinome, J. Med. Chem., 60, 2879, 10.1021/acs.jmedchem.6b01815 · DOI · Paper page
- Zhou, 2010, A structure-guided approach to creating covalent FGFR inhibitors, Chem. Biol., 17, 285, 10.1016/j.chembiol.2010.02.007 · DOI · Paper page
- Zhu, 2001, Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer’s disease, J. Neurochem., 76, 435, 10.1046/j.1471-4159.2001.00046.x · DOI · Paper page
Cited by
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening
Resnick, E., Bradley, A., Gan, J., Douangamath, A., Krojer, T., Sethi, R., Geurink, P. P., Aimon, A., Amitai, G., Bellini, D., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b02822 · Cited by 335
Self-citationRecent Advances in Selective and Irreversible Covalent Ligand Development and Validation
Zhang, T., Hatcher, J. M., Teng, M., Gray, N. S., & Kostic, M. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.09.012 · Cited by 178
“, 2018), and MKK7, an upstream activator of JNK kinases (Shraga et al., 2019).”
Background
Metadata
- Authors
- Shraga, A., Olshvang, E., Davidzohn, N., Khoshkenar, P., Germain, N., Shurrush, K., Carvalho, S., Avram, L., Albeck, S., Unger, T., Lefker, B., Subramanyam, C., Hudkins, R. L., Mitchell, A., Shulman, Z., Kinoshita, T., & London, N.
- Venue
- Cell Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 26
- Issue
- 1
- Pages
- 98-108.e5
- ISSN
- 2451-9448 (ISSN-L)
- 2451-9456
- OpenAlex
- W2900458600
- Cited by
- 64
- References
- 14
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 381 d)
- Funders
- Israel Science Foundation (1097/16)
- German-Israeli Foundation (I-2483-302.5/2017)
- Teva National Network of Neuroscience
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor. https://app.cochat.ai/papers/10.1016/j.chembiol.2018.10.011
- The paper
- Shraga, A., Olshvang, E., Davidzohn, N., Khoshkenar, P., Germain, N., Shurrush, K., Carvalho, S., Avram, L., Albeck, S., Unger, T., Lefker, B., Subramanyam, C., Hudkins, R. L., Mitchell, A., Shulman, Z., Kinoshita, T., & London, N. (2019). Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor. Cell Chemical Biology. https://doi.org/10.1016/j.chembiol.2018.10.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.